19F Thoracic Radiotherapy for Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to determine the feasibility and efficiency of incorporating 19F MR functional lung imaging into the routine assessment of lung cancer patients prior to thoracic radiotherapy.

Detailed Description
-----------------
Primary Objective: Determine feasibility by evaluating if: PO1: Patients diagnosed with lung cancer are able to successfully complete pre- and post-radiotherapy 19F MR imaging scans as scheduled. Secondary Objective: Determine efficiency by evaluating if: SO1: Determine efficiency by evaluating if 19F MRI data can be successfully analyzed and incorporated into the radiation planning system. SO2: Determine efficiency by evaluating if the incorporated 19F MRI functional data can be successfully used to generate radiotherapy plan in a timely manner. SO3: Determine if pre- and post radiotherapy 19F MRI scans can be readily compared to observe changes in pulmonary function. Hypotheses Investigators hypothesize that functional 19F MR imaging assessment is feasible in the lung cancer patient population and that the acquired images can be efficiently analyzed and integrated into radiotherapy planning.

Official Title
-----------------
Feasibility Study to Determine Utility of 19F MRI for Regional Pulmonary Function Assessment in Patients Receiving Thoracic Radiotherapy for Lung Cancer

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Drug: Perfluorinated Gas/Oxygen Mixture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject has histologic or cytologic confirmation of lung cancer (NSCLC or Small cell) and has been recommended thoracic radiotherapy as part of standard of care management. Ability to undergo MR imaging, tolerate breath hold procedures and follow direction during the imaging process Karnofsky performance status ≥60, with expected survival of ≥6 months At least 18 years of age Patient is not pregnant Patient can be reliably reached for post-MRI follow up AE check. Patient able to sign a study specific informed consent form. Exclusion Criteria: Any condition including, metallic implants or cardiac pacemakers that makes the candidate ineligible for MR imaging. (MRI research screening form will be completed prior to each MRI scan). Malignant pleural effusion or pericardial effusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients diagnosed with Lung cancer<br>patients diagnosed with Lung cancer and Thoracic radiotherapy | Drug: Perfluorinated Gas/Oxygen Mixture<br>* 19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, < 1 hour<br>* Other names: Perfluorinated Propane Imaging;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of study patients consented (maximum 8)in order to result in 5 patients successfully completing both 19F functional MR imaging data sets |  | 4 months | 
| Proportion of study patients that successfully return for a re-assessment 19F MRI scan after completing radiotherapy. |  | 6 weeks after completing RT | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thoracic Radiation therapy, Lung Function